LACTOLOGY FOUNDATION

Lactulose-containing medicines in ATC class A06AD61 (lactulose, combinations) are considered compatible with breastfeeding, with minimal systemic absorption and negligible transfer into breast milk; however, monitoring for maternal gastrointestinal adverse effects and electrolyte imbalance is advised, especially with prolonged use.medpedia.framar+5

Pharmacological class and composition

Medicines classified under ATC A06AD61 contain lactulose in fixed combinations with other active substances, generally used as osmotic laxatives for the treatment of constipation.drugbank+2
Lactulose is a synthetic disaccharide (galactose–fructose) that is poorly absorbed in the small intestine and reaches the colon largely unchanged.trc-p+1
The co‑components in A06AD61 products are typically other laxative agents or phytotherapeutic/adjunct ingredients, selected to enhance stool softening, bowel evacuation, or tolerability.westmidspallcare+2

Mechanism of action and therapeutic use

Lactulose acts as an osmotic laxative by increasing intraluminal osmotic pressure, leading to retention of water in the bowel and an increase in stool volume.nhs+2
Colonic bacteria metabolise lactulose to low‑molecular‑weight organic acids, which further augment osmotic load and stimulate peristalsis, facilitating defecation.drugbank+2
Clinically, A06AD61 lactulose combinations are indicated for the relief of chronic constipation and bowel cleansing where a gradual, softening laxative effect is desired rather than rapid stimulation.bnf.nice+2

General toxicological profile

Because lactulose is minimally absorbed (often <3% of an oral dose), systemic exposure is low and systemic toxicity is rare at therapeutic doses.doctronic+2
Typical adverse reactions are gastrointestinal and dose‑dependent: abdominal pain, flatulence, nausea, vomiting and diarrhoea; prolonged or high‑dose use may cause disturbances in water–electrolyte balance.medpedia.framar+2
Clinically relevant toxicity is mainly related to excessive dosing or chronic unmonitored use, with risks of dehydration, hyponatraemia, hypokalaemia and symptomatic diarrhoea in susceptible patients (elderly, those on diuretics or with cardiac/renal disease).sps+3

Contraindications and cautions

Lactulose combinations are contraindicated in patients with known hypersensitivity to lactulose or any excipient in the product, and in those with inflammatory bowel diseases such as Crohn’s disease or ulcerative colitis.bnf.nice+1
They should be used cautiously in patients with unexplained abdominal pain, suspected intestinal obstruction, or conditions predisposing to electrolyte imbalance, with dose adjustment and clinical monitoring as needed.nhs+2
In hereditary galactosaemia or fructose intolerance, certain lactulose formulations may be unsuitable because of the sugar content, and specialist advice is recommended.drugbank+1

Lactation toxicology and breastfeeding safety

Owing to poor oral absorption and predominant local action in the colon, only negligible amounts of lactulose reach maternal systemic circulation and, consequently, breast milk.ncbi.nlm.nih+3
Available lactation references consider lactulose one of the preferred osmotic laxatives in breastfeeding, and several expert sources classify it as compatible or “laxative of choice” during lactation when clinically indicated.breastfeedingnetwork+3
Clinical and pharmacokinetic data indicate that even if trace quantities were to appear in milk, they would be rapidly eliminated by the infant and are not expected to exert pharmacological effects or cause diarrhoea in breastfed infants.pmc.ncbi.nlm.nih+2

For lactulose combinations (A06AD61), lactation safety is primarily determined by the additional components; however, most osmotic and bulk-forming laxatives are considered suitable in breastfeeding because of minimal systemic and milk transfer.sps+1
When co‑formulated with stimulant laxatives or herbal components, routine, long‑term use should be avoided without medical supervision, and preference should be given to the lowest effective dose and shortest duration compatible with therapeutic goals.breastfeedingnetwork+2
No specific adverse reactions in breastfed infants have been convincingly linked to maternal use of lactulose or its common combinations, and no special timing relative to feeds is usually required.drugs+2

Dose, duration and monitoring in breastfeeding women

Typical adult doses of lactulose for constipation range around 15–30 mL once or twice daily, titrated to response; similar dosing applies when lactulose is part of combination products, according to individual product labelling.geneesmiddeleninformatiebank+2
In breastfeeding women, osmotic laxatives such as lactulose should ideally be used after non‑pharmacological measures (optimised fibre, fluid intake and physical activity) have proven insufficient, and therapy should be regularly reviewed.breastfeedingnetwork+1
During lactulose combination treatment, breastfeeding mothers should be monitored for persistence of constipation, severity of diarrhoea, abdominal pain, and signs of dehydration or electrolyte imbalance, with dose reduction or discontinuation as appropriate.medpedia.framar+2

Clinical recommendations for lactation-toxicology

From a lactation-toxicology perspective, lactulose combinations in A06AD61 can be considered compatible with breastfeeding when used at standard doses, with low risk for breastfed infants.ncbi.nlm.nih+3
They are suitable options for short‑ to medium‑term management of constipation in nursing mothers, including postpartum constipation, provided that the maternal clinical situation (comorbidities, concomitant drugs) does not contraindicate osmotic laxatives.pmc.ncbi.nlm.nih+2
As with all laxatives, chronic unsupervised use should be avoided; individual risk–benefit assessment, attention to maternal hydration and electrolytes, and preference for agents with minimal systemic absorption support safe use during lactation.sps+3